A Collaboration to Advance Biosimilar Development
Opal BioPharma, a pioneering end-to-end biologics manufacturer in the GCC, and Polpharma Biologics, a leading European biosimilars developer, are pleased to announce a collaboration to create high-quality biosimilar cell lines for the GCC and wider MENA region.
This partnership brings together Opal BioPharma’s expanding infrastructure and regional market access with Polpharma Biologics’ extensive technical expertise in cell line development and EMA-aligned regulatory pathways. The collaboration is designed to accelerate biosimilar development and support sustainable access to advanced biologic therapies across the region.
“This partnership represents a key milestone in advancing our mission to build a self-sufficient and innovation-driven biologics ecosystem in the GCC,” said Saman Hosseininasab, CEO of Opal BioPharma. “By combining our local infrastructure with Polpharma Biologics’ world-class development capabilities, we are creating a strong foundation for long-term impact.”
“We’re proud that our know-how can help our partners bring impactful therapies to life. By providing high-quality cell line development, we help them move faster — and ultimately reach more patients with life-changing biologics,” said Konstantin Matentzoglu, Member of the Supervisory Board of Polpharma Biologics Group B
As healthcare systems in the GCC and MENA increasingly focus on local production, regulatory independence, and sustainable access, this partnership reflects a shared commitment to delivering innovation and building regional capability.
Both organizations are confident that this collaboration will pave the way for future growth, expanded partnerships, and greater access to life-changing therapies.
